Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences

Rhea-AI Summary

Arcus Biosciences to participate in upcoming investor conferences in September

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:

2023 Wells Fargo Healthcare Conference
Date: Wednesday, September 6^th, 2023 at 10:15 a.m. ET
Location: Boston, MA
Format: Fireside Chat

Citi 18^th Annual BioPharma Conference
Date: Wednesday, September 6^th, 2023 at 3:30 p.m. ET
Location: Boston, MA
Format: Company Panel — Immuno-Oncology

Morgan Stanley 21^st Annual Global Healthcare Conference
Date: Tuesday, September 12^th, 2023 at 4:15 p.m. ET
Location: New York, NY
Format: Fireside Chat

2023 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 26^th, 2023 at 10:20 a.m. ET
Location: New York, NY
Format: Fireside Chat

Live webcasts of the fireside chats and panel will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230823679974/en/

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Investor Inquiries

Pia Eaves (Banerjee)

Head of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Source: Arcus Biosciences